44 - Immunotherapies for Substance Use Disorders: State-of-the-Art Approaches

Session Chair(s)

• Marco Pravetoni

  University of Washington

• Sandra Comer

  Columbia University

Deaths attributed to synthetic opioids, such as fentanyl, and stimulants, such as cocaine and methamphetamine, have increased tremendously in the past year. Although several effective medications are available for treating opioid use disorder, relapse rates are high and medications for treating opioid overdose, such as naloxone, may be less effective against synthetic opioids compared to heroin. No medications have been approved in the U.S. for treating stimulant use disorders. Monoclonal antibodies and vaccines represent an alternative approach to treating overdose and substance use disorders. This symposium will provide an update on immunotherapies that are currently in clinical testing.

Presentations:

• 1:30 PM – 1:35 PM

  Introduction
• 1:35 PM – 2:00 PM

  Pre-clinical and Clinical Development of a Humanized Anti-cocaine Monoclonal Antibody
  

  Speaker: Andrew Norman – University of Cincinnati
• 2:00 PM – 2:25 PM

  IXT-m200 for METH Use Disorder: Phase 2 Data and Approaches to Treatment with a METH Antibody
  

  Speaker: Keith Ward – Intervexion Therapeutics LLC
• 2:25 PM – 2:50 PM

  Development and Translation of Vaccines and Antibody-based Therapeutics for Opioid Use Disorders and Overdose
  

  Speaker: Marco Pravetoni – University of Washington
• 2:50 PM – 3:00 PM

  "Late Night" Style Q&A